Adaptive behavior in adolescents and adults with Down syndrome: Results from a 6-month longitudinal study.


Journal

American journal of medical genetics. Part A
ISSN: 1552-4833
Titre abrégé: Am J Med Genet A
Pays: United States
ID NLM: 101235741

Informations de publication

Date de publication:
01 2019
Historique:
received: 16 01 2018
revised: 09 09 2018
accepted: 10 10 2018
pubmed: 21 12 2018
medline: 13 2 2020
entrez: 21 12 2018
Statut: ppublish

Résumé

Measures of adaptive behavior are important in the assessment and treatment of individuals with intellectual disabilities (ID). The purpose of the current study was to evaluate the stability of an established and a novel measure of adaptive behavior over time, and their suitability as outcome measures in clinical trials targeting individuals with Down syndrome (DS). This 6-month, longitudinal, noninterventional, multinational study included adolescents (12-17 years) and adults (18-30 years) with DS. Participants were from seven countries (11 different sites) with English, Spanish and French as their native language. The Vineland Adaptive Behavior Scales-II (VABS-II) and a newly developed Clinician Global Impression (CGI) scale were administered at baseline, 1 and 6 months. Adults had lower composite standard scores on all domains of the VABS-II compared with adolescents. The communication domain was a weakness relative to the socialization and daily living skills domains on the VABS-II and the CGI-Severity scale. These findings were stable over 6 months, as exhibited by high intraclass correlations (>0.75). These results provide valuable baseline data for use in trial design and endpoint selection for studies including individuals with DS. ClinicalTrials.gov identifier: NCT01580384.

Identifiants

pubmed: 30569586
doi: 10.1002/ajmg.a.60685
doi:

Banques de données

ClinicalTrials.gov
['NCT01580384']

Types de publication

Clinical Trial, Phase II Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

85-93

Subventions

Organisme : F. Hoffmann-La Roche
Pays : International

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Gail A Spiridigliozzi (GA)

Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina.

Celia Goeldner (C)

F. Hoffmann-La Roche, Roche Pharma Research and Early Development, Neuroscience, Roche Innovation Center Basel, Basel, Switzerland.

Jamie Edgin (J)

Department of Psychology, University of Arizona, Tucson, Arizona.

Sarah J Hart (SJ)

Department of Pediatrics, Duke University Medical Center, Durham, North Carolina.

Jana Noeldeke (J)

F. Hoffmann-La Roche, Roche Pharma Research and Early Development, Neuroscience, Roche Innovation Center Basel, Basel, Switzerland.

Lisa Squassante (L)

F. Hoffmann-La Roche, Roche Pharma Research and Early Development, Neuroscience, Roche Innovation Center Basel, Basel, Switzerland.

Jeannie Visootsak (J)

F. Hoffmann-La Roche, Roche Pharma Research and Early Development, Neuroscience, Roche Innovation Center, New York, New York.

Omar Khwaja (O)

F. Hoffmann-La Roche, Roche Pharma Research and Early Development, Neuroscience, Roche Innovation Center Basel, Basel, Switzerland.

Priya S Kishnani (PS)

Department of Pediatrics, Duke University Medical Center, Durham, North Carolina.

Xavier Liogier d'Ardhuy (X)

F. Hoffmann-La Roche, Roche Pharma Research and Early Development, Neuroscience, Roche Innovation Center Basel, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH